GO2 Lung Cancer Foundation Designates Roswell Park as a Place of Excellence for Screening

Cancer center recognized for following best practices in field

  • Designated centers demonstrate best practices outlined by NCCN, ACR
  • Roswell Park’s Lung Cancer Screening Program offers low-dose CT scans
  • Center’s program diagnoses 70 percent of lung cancers at early stage

The efforts of the Roswell Park Comprehensive Cancer Center to provide opportunities for early detection of lung cancer to the community have won a prestigious GO2 Foundation for Lung Cancer Screening Center of Excellence.

Technical governing bodies such as the American College of Radiology (ACR) and the National Comprehensive Cancer Network (NCCN) offer clear information on who is a qualified candidate and comply with comprehensive best practices through the approved centers of the non-profit organization.

“We are proud and honored to be working with Roswell Park Comprehensive Cancer Center as a GO2 Foundation for Lung Cancer Screening Center of Excellence,” says Foundation Co-Founder, President and CEO Laurie Fenton Ambrose. “Their commitment to practice responsible lung cancer screening will lead to advancements in research and many lives saved They are an example to follow.”

The screening system of Roswell Park focuses on people at high risk which involves documenting the history of treatment, physical examination, and taking a low-dose chest CT scan (LDCT). At an early stage, our experts diagnosed 70% of cancers compared to national averages that measure the same percentage at advanced stages.

Our lung cancer screening team brings knowledge and passion to the care we deliver, and this designation confirms it,” said Mary Reid, MPSH, PhD, Director of Cancer Screening and Survivorship. “Our comprehensive approach sets us apart because it ensures that patients have access to state-of-the art screening technology, personalized medicine, clinical trials and support from psychosocial and smoking-cessation counselors.”

Roswell Park has previously received the Screening Center of Excellence designation from the Lung Cancer Alliance, a founding member of the GOFoundation for Lung Cancer.

###

For an online version of this release, please visit: https://www.roswellpark.org/media/news/go2-foundation-lung-cancer-designates-roswell-park-screening-center-excellence

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

 

GO2 Lung Cancer Foundation Designates Roswell Park as a Place of Excellence for Screening

GO2 Lung Cancer Foundation Designates Roswell Park as a Place of Excellence for Screening

Roswell Park

3 weeks
5 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Light-to-Moderate Exercise May Provide Sickle Cell Disease Benefits
Category: News
0 Views
Cancer-News 14 minutes
Renal Case Presentations
Renal Case Presentations
Category: Kidney Cancer
5 Views
kidneycancer 18 hours
Radiation to Prime the Immune System
Radiation to Prime the Immune System
Category: Kidney Cancer
4 Views
kidneycancer 20 hours
ProVent Trial: When Will There Be Results?
ProVent Trial: When Will There Be Results?
Category: Prostate Cancer
3 Views
CURC 21 hours
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
How is Immunotherapy Used in Prostate Cancer? @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
ProVent Trial Changing AS Landscape @UrologyUS
ProVent Trial Changing AS Landscape @UrologyUS
Category: Prostate Cancer
3 Views
CURC 22 hours
Current Treatment Options in the ProVent Trial
Current Treatment Options in the ProVent Trial
Category: Prostate Cancer
3 Views
CURC 22 hours
Phase 3 ProVent Clinical Trial @UrologyUS
Phase 3 ProVent Clinical Trial @UrologyUS
Category: Prostate Cancer
4 Views
CURC 23 hours
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Loss of SETD2 is associated with dysregulation of protein translation in clear cell renal cell carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 2 days
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Immune Correlates and Prognostic Significance of CD73 Expression in Renal Cell Carcinoma
Category: Kidney Cancer
10 Views
kidneycancer 2 days